TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11352436

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 100mg twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 200mg twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 600mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9229034

Group type: EXPERIMENTAL
Intervention: Antimanic treatment (specifics not provided)
Number of subjects: 27
Study: 8105716

Group type: EXPERIMENTAL
Intervention: 0.105 mg/kg MIV (1.5 x ED95) and H1/H2 antagonist
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.105 mg/kg MIV and placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.21 mg/kg MIV (3 x ED95) and H1/H2 antagonist
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.21 mg/kg MIV and placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: H1/H2 premedication
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3145665

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms, q.i.d. for 4 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cimetidine 1200 mg, q.i.d. for 4 weeks
Number of subjects: 116
Study: 28648577

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 203
Study: 27793166

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b therapy at 1.5 mcg/kg for 48 weeks
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: HBsAg <1500 IU/mL at week 12
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: HBsAg decrease >1.5 logIU/mL at week 12
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: HBsAg >20,000 IU/mL at week 12
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: HBsAg >20,000 IU/mL at week 24
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: HBsAg level or changes at weeks 12 and 24 combined with HBeAg or HBV DNA
Number of subjects: 171
Study: 24346752

Group type: EXPERIMENTAL
Intervention: Haloperidol 15 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Risperidone 2 to 6 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Risperidone and Olanzapine groups
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 43

Group type: COMPARATOR
Intervention: All drug groups
Number of subjects: 43
Study: 24188719

Group type: EXPERIMENTAL
Intervention: LINDA intervention (n = 1,537) received a 20‐minute individualized lifestyle counseling session followed by further support at six‐monthly follow-ups for 1.5‐2.5 years.
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Support on healthy physical activity behaviors.
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Support on healthy sleeping behaviors.
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Support on healthy dietary behaviors.
Number of subjects: 3059

Group type: COMPARATOR
Intervention: Control group (received counseling on sexual health and contraception).
Number of subjects: 3059
Study: 21109113

Group type: EXPERIMENTAL
Intervention: Erectile dysfunction (ED) at baseline
Number of subjects: 6304
Study: 18423009

Group type: EXPERIMENTAL
Intervention: Oral melatonin 10 mg administered at 9 p.m. for four nights
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo administered at 9 p.m. for four nights
Number of subjects: 24
Study: 15847226

Group type: EXPERIMENTAL
Intervention: Feature generation task (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued recall task (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feature verification tasks (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feature verification tasks with priming biases minimized (Experiment 4)
Number of subjects: 0
Study: 12528027

Group type: EXPERIMENTAL
Intervention: Intensive Care Information System (ICIS)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Paper-based registration
Number of subjects: 145
Study: 10574164

Group type: EXPERIMENTAL
Intervention: Subjective swelling of the hand
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Positive electrodiagnostic findings
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Phalen test and carpal compression test
Number of subjects: 186
Study: 8916314

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) 12 mg/m2/d for 3 days and cytosine arabinoside (Ara‐C) 100 mg/m2/d for 7 days
Number of subjects: 26
Study: 1858985

Group type: COMPARATOR
Intervention: Placebo pretreatment before tracheal extubation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg IV) pretreatment before tracheal extubation
Number of subjects: 25
Study: 30820037

Group type: EXPERIMENTAL
Intervention: Persons with NF1
Number of subjects: 550
Study: 28932131

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with subdiaphragmatic lidocaine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 84

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 84
Study: 26905266

Group type: EXPERIMENTAL
Intervention: Mesalazine modified-release tablets (MR group, n = 126)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Other enteric-coated tablets (EC group, n = 125)
Number of subjects: 251
Study: 25134737

Group type: EXPERIMENTAL
Intervention: Reduced-salt exposure
Number of subjects: 135

Group type: COMPARATOR
Intervention: Regular-salt exposure
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Alternating reduced- and regular-salt exposure
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Gradually declining salt concentration exposure
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 135
Study: 21512102

Group type: EXPERIMENTAL
Intervention: Intensive reading intervention (50-minute daily sessions in groups of 2-4 students)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No researcher-provided intervention (comparison group)
Number of subjects: 41
Study: 19175878

Group type: EXPERIMENTAL
Intervention: lamivudine + vaccine + HBIg
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo + vaccine + HBIg
Number of subjects: 150
Study: 17722445

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol plus dexamethasone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nebulized salbutamol
Number of subjects: 49
Study: 15889321

Group type: EXPERIMENTAL
Intervention: Postprandial aspart insulin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Preprandial aspart insulin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both preprandial and postprandial aspart insulin
Number of subjects: 18
Study: 12529065

Group type: EXPERIMENTAL
Intervention: Enhanced standard program (two short individual sessions and a brief follow-up session)
Number of subjects: 4074

Group type: COMPARATOR
Intervention: Standard first-offender program
Number of subjects: 4074

Group type: EXPERIMENTAL
Intervention: Enhanced standard program
Number of subjects: 4074
Study: 9698977

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Food
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Verbal expectancy manipulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8620667

Group type: EXPERIMENTAL
Intervention: Zileuton (800mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naproxen (500mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coadministration of zileuton and naproxen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zileuton
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 24
Study: 2666559

Group type: EXPERIMENTAL
Intervention: Non-pharmacological therapy (started after 1 year for G1)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Non-pharmacological therapy (used from the beginning for G2)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Non-pharmacological therapy (for both groups)
Number of subjects: 400
Study: 371032

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 0
Study: 30391434

Group type: EXPERIMENTAL
Intervention: Indomethacin plus epinephrine (IE)
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Indomethacin plus saline (IS)
Number of subjects: 1158
Study: 28865550

Group type: EXPERIMENTAL
Intervention: Time-lapse system (TLS)
Number of subjects: 378
Study: 25838254

Group type: EXPERIMENTAL
Intervention: Tivantinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24142473

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6 %
Number of subjects: 518

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 518
Study: 21132438

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Contrast Water Therapy (CWT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Passive Recovery (PAS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Temperate Water Immersion (TWI)
Number of subjects: 41
Study: 19860495

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+) until surgical closure of the soft palate at approximately 52 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (IO-)
Number of subjects: 54
Study: 16770975

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simulated acupuncture (Control)
Number of subjects: 50
Study: 16237983

Group type: EXPERIMENTAL
Intervention: Intravascular irradiation therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonradiation (stenting only)
Number of subjects: 15
Study: 11795586

Group type: EXPERIMENTAL
Intervention: The Coalition for Youth Quality of Life Project (ecological and participatory approach)
Number of subjects: 791
Study: 9428121

Group type: EXPERIMENTAL
Intervention: 2 grams a day of oral acyclovir for 16 weeks after transplantation
Number of subjects: 73

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 73
Study: 8515787

Group type: EXPERIMENTAL
Intervention: 60 mg of vesnarinone per day
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: 120 mg of vesnarinone per day
Number of subjects: 477
Study: 2893583

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 220

Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Diluted albumin
Number of subjects: 220
Study: 31094640

Group type: COMPARATOR
Intervention: Sham KT + BE
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: KT + BE
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: KT in isolation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham KT
Number of subjects: 48
Study: 31662037

Group type: EXPERIMENTAL
Intervention: Intravenous and intra-arterial therapies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Secondary prevention measures
Number of subjects: 100
Study: 28101887

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abiraterone acetate (AA) with prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzalutamide or AA
Number of subjects: 0
Study: 26079223

Group type: EXPERIMENTAL
Intervention: 1.2 g/d GAA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2.4 g/d GAA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 4.8 g/d GAA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23511822

Group type: EXPERIMENTAL
Intervention: fMRI during an 8-minute auditory semantic decision task
Number of subjects: 35
Study: 21650082

Group type: EXPERIMENTAL
Intervention: Test formulation of perindopril erbumine 4 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of perindopril erbumine 4 mg
Number of subjects: 20
Study: 19167636

Group type: EXPERIMENTAL
Intervention: Cibenzoline (Cib, 70 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Pilsicainide (Pil, 50 mg)
Number of subjects: 68
Study: 16750796

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily
Number of subjects: 233

Group type: COMPARATOR
Intervention: Routine treatment (including gabapentin, venlafaxine, amitriptyline)
Number of subjects: 233
Study: 15187799

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral therapy (TF-CBT)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Child-centered therapy
Number of subjects: 229
Study: 11483229

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 25
Study: 10806698

Group type: EXPERIMENTAL
Intervention: Misoprostol (600 micrograms orally when peritoneum was incised)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Misoprostol (600 micrograms orally) and Oxytocin (20 IU injected into uterine muscle immediately after delivery)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Oxytocin (20 IU injected into uterine muscle and 20 IU intravenous injection immediately after delivery)
Number of subjects: 182
Study: 7827631

Group type: EXPERIMENTAL
Intervention: Prophylactic knee braces; 23 knee injuries in 21,640 exposures
Number of subjects: 8

Group type: COMPARATOR
Intervention: No prophylactic knee braces; 26 knee injuries in 19,484 exposures
Number of subjects: 8
Study: 3137469

Group type: EXPERIMENTAL
Intervention: FDC + ICRF‐187
Number of subjects: 92

Group type: COMPARATOR
Intervention: FDC
Number of subjects: 92
Study: 29528117

Group type: EXPERIMENTAL
Intervention: Dopamine (2 μg kg-1 min-1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% O2)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (i.v. saline)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (i.v. dopamine)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (hyperoxia)
Number of subjects: 13
Study: 26951940

Group type: EXPERIMENTAL
Intervention: Doxycycline 40‐mg modified‐release capsules
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 24721108

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention based on problem-solving therapy for glioma patients with depressive symptoms.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waiting list control group for glioma patients.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-central nervous system malignancy control group (haematological cancer patients).
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waiting list control group.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-central nervous system malignancy control group.
Number of subjects: 126
Study: 23570677

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (8 g magnesium sulphate heptahydrate in 50 ml infusion over 30 minutes)
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Placebo (isotonic sodium chloride solution 0.9% in 50 ml infusion over 30 minutes)
Number of subjects: 1676
Study: 20172643

Group type: EXPERIMENTAL
Intervention: Two simple questions assessing everyday activities and mental recovery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark 3 (HUI3)
Number of subjects: 32
Study: 18772586

Group type: EXPERIMENTAL
Intervention: Fish oil-enriched spread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control spread
Number of subjects: 0
Study: 16616347

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 72

Group type: COMPARATOR
Intervention: Continued medical therapy (control group)
Number of subjects: 72
Study: 12243220

Group type: EXPERIMENTAL
Intervention: Proactive problem-solving skills
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Subtypes of problem-solving skills
Number of subjects: 32
Study: 9539998

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Diabetic neuropathy
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Overt albuminuria
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Increasing retinopathy stage
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Increasing UAE stage
Number of subjects: 419
Study: 8024262

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine (low and medium doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose scopolamine
Number of subjects: 0
Study: 2919766

Group type: EXPERIMENTAL
Intervention: Tetracaine 1% (hypobaric 0.25%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (hypobaric 0.25%)
Number of subjects: 30
Study: 1056947

Group type: EXPERIMENTAL
Intervention: Newly developed dental training simulator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional training method (Control)
Number of subjects: 30
Study: 30589502

Group type: EXPERIMENTAL
Intervention: Guided sleeve height of 2 mm, 4 mm, 6 mm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drilling distance of 18 mm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided key height of 3 mm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total drilling distance below the guided sleeve
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided key height above the sleeve
Number of subjects: 0
Study: 28096208

Group type: EXPERIMENTAL
Intervention: Alteplase administered at the CT scanner
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patient brought directly to CT on emergency medical services stretcher
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patient registered as unknown
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: STAT stroke protocol implemented
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Stroke severity (NIHSS score 6-8)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Stroke severity (NIHSS score >8)
Number of subjects: 350
Study: 24187862

Group type: EXPERIMENTAL
Intervention: Fuzhengpaidu granule (FZPDG) for six months
Number of subjects: 34
Study: 21376167

Group type: EXPERIMENTAL
Intervention: Phenazopyridine hydrochloride
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 19660517

Group type: EXPERIMENTAL
Intervention: ARC-I (saliva contamination, blot-dried)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARC-II (saliva contamination, rinse, blot-dried)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARC-III (saliva contamination, rinse, re-etch, rinse, blot-dried)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-I (saliva contamination, dried)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-III (primer, saliva contamination, dried)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-IV (primer, saliva contamination, dried, primer re-applied)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-II (saliva contamination, rinse, dried)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-V (primer, saliva contamination, rinse, dried, primer re-applied)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ARC-control (uncontaminated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PF-control (uncontaminated)
Number of subjects: 0
Study: 17270614

Group type: EXPERIMENTAL
Intervention: Urethral botulinum A toxin (BoNT‐A) injection
Number of subjects: 27
Study: 15520109

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) and supplemental iron therapy
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo/control with supplemental iron alone
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 172
Study: 11274622

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9488514

Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP)
Number of subjects: 705

Group type: COMPARATOR
Intervention: No Omentoplasty (NO)
Number of subjects: 705
Study: 8043312

Group type: EXPERIMENTAL
Intervention: Spa treated with lithium ion (40 +/- 5 ppm)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control spa (no additional lithium ion, background levels of approximately 0.02 ppm)
Number of subjects: 53
Study: 2197681

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 996

Group type: COMPARATOR
Intervention: Placebo (for both interventions)
Number of subjects: 996
Study: 1101130

Group type: EXPERIMENTAL
Intervention: Dexivacaine 2%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepivacaine 3%
Number of subjects: 0
Study: 30634923

Group type: EXPERIMENTAL
Intervention: Discontinuously supervised aerobic exercise training program (18 months, 3 days/week)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Behavioral counseling on physical activity and diet
Number of subjects: 300
Study: 28218006

Group type: EXPERIMENTAL
Intervention: Red laser (660 nm) treatment with 4 j/cm² in TMJs and 8 j/cm² in muscles, applied in three sessions.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Infrared laser (790 nm) treatment with 4 j/cm² in TMJs and 8 j/cm² in muscles, applied in three sessions.
Number of subjects: 19
Study: 25708022

Group type: EXPERIMENTAL
Intervention: 400 mg droxidopa
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 600 mg droxidopa
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 23479675

Group type: EXPERIMENTAL
Intervention: Neutral shoulder position
Number of subjects: 362

Group type: COMPARATOR
Intervention: Retracted shoulder position
Number of subjects: 362
Study: 21632496

Group type: EXPERIMENTAL
Intervention: Elevated baseline white blood cell count (WBCc)
Number of subjects: 3193

Group type: EXPERIMENTAL
Intervention: High WBCc (>11,000 per 1 mm³)
Number of subjects: 3193